Stocks ticked slightly higher as investors awaited results from the two-day Fed policy meeting, which concludes today. Markets seem to have priced in a third consecutive 75 basis point rate hike. However, uncertainty remains over the central bank’s longer-term projections.
“Our sense is that markets could be set up for a short-lived relief rally if the Fed hikes by +75bps and Powell doesn’t ratchet up his hawkish rhetoric even further,” said Wolfe Research’s Chris Senyek. “That said, we don’t anticipate having to change our intermediate-term bearish call.”
Regardless of what’s happening elsewhere in the market, biopharma is a great place to look for stocks to pack into your portfolio because there’s always an illness that can be treated more effectively in the future than it is being treated today.
Our trade alert features an established drug maker with an excellent approval history. Their treatments have been widely trusted for years, and currently, they have multiple promising projects in the pipeline.
A Return to Normal? PhD Economist: “Don’t Bet on It”
According to former Goldman Sachs executive, Nomi Prins…
Americans who are hoping for a ‘return to normal’ are going to be shocked when they see what happens next in America.
She says, “If you’re betting your job, savings, or retirement accounts on a return to ‘normal’ you’re about to be left behind by a brand-new crisis few see coming.”
Go here now to see America’s next crisis
Vertex Pharmaceuticals (VRTX) is the undisputed leader in cystic fibrosis therapies. The company’s portfolio of approved CF drugs will deliver at least an estimated $8.4 billion this year, made possible by intense market penetration and decades-long devotion to research and development in the space.
So far, the company has been highly accountable, proving to regulators that its products are effective and safe for broader and more comprehensive populations of patients. It has also remained strongly profitable and continued to expand revenue within the CF market at a steady pace.
If management’s plans for expanded approvals for younger age cohorts continue to come to fruition over the next few years, Vertex will eventually be treating as many as 90% of all people with CF. That means investors can look forward to a steadily increasing flow of new revenue and expanded approvals, which should significantly support the stock’s price.
Furthermore, the company is moving its pipeline beyond CF with a handful of mid-stage clinical programs for pain relief, kidney disease, and genetic hematologic disorders like sickle cell disease. In other words, even if it eventually completely corners the entire market for CF therapies, there will still be other opportunities for growth.
Of 26 analysts offering recommendations for VRTX, 18 give the stock a Buy rating, and 9 rate it a Hold. There are no Sell ratings. It seems likely that Vertex will reward patient investors as the steadily growing biopharma company seems ripe for expansion for years to come.
Where to invest $1,000 right now...
Before you consider buying VRTX, you'll want to see this.
Investing legend, Keith Kohl just revealed his #1 stock for 2022...
And it's not VRTX.
Jeff Bezos, Peter Thiel, and the Rockefellers are betting a colossal nine figures on this tiny company that trades publicly for $5.
Keith say’s he thinks investors will be able to turn a small $50 stake into $150,000.
Find that to be extraordinary?
But you have to act now, because a catalyst coming in a few weeks is set to take this company mainstream... And by then, it could be too late.
A company with 400 million ‘patents’
One company has quietly compiled more than 400 million official trade secrets.
Trade secrets are like patents in that they protect valuable and proprietary information…
But unlike patents, trade secrets take less time to register… and more importantly, they never expire.
Which is a huge advantage for this little-known company.
You see, this company is using these trade secrets to build the world’s largest “codebase,” which will bethe key to it becoming “America’s Next Big Monopoly.”
Not surprisingly, Wall Street is starting to take notice. And the smart money is already pouring in.
Tech investor Cathie Wood has invested over $80 million already, and Microsoft founder Bill Gates has invested as well.
Get the details here before this story hits the mainstream media.